Monoclonal Gammopathy of Undetermined Significance Clinical Trial
Official title:
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma (ORIGIN Study)
The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease (asymptomatic) develop multiple myeloma, while others do not. Studying markers such as age, level of proteins in blood, percent of abnormal blood cells in the bone marrow, genes in the abnormal blood cells, and bone abnormalities may help researchers to validate clinical and genomic predictors for future use in clinical practice.
PRIMARY OBJECTIVE: I. To determine the rate of progression to multiple myeloma after 3 years of follow up. SECONDARY OBJECTIVES: I. To describe baseline patient characteristics and clinical variables. II. To identify molecular and genetic correlates that may predict for progression to multiple myeloma (MM). OUTLINE: Patients undergo collection of blood samples every 6 months for 3 years. Patients may also undergo a biopsy, x-rays, positron emission tomography (PET)/computed tomography (CT) scans, and/or magnetic resonance imaging (MRI) scans to check the status of disease at the discretion of the treating physician. After completion of 3 years on study, patients are followed up every 6-12 months thereafter. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05969821 -
Clonal Hematopoiesis of Immunological Significance
|
||
| Not yet recruiting |
NCT04702932 -
Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies
|
||
| Active, not recruiting |
NCT03327597 -
Iceland Screens, Treats or Prevents Multiple Myeloma
|
N/A | |
| Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
| Completed |
NCT04439006 -
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
|
Phase 1 | |
| Completed |
NCT01955395 -
Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma
|
N/A | |
| Completed |
NCT01219010 -
A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT01237054 -
Imaging in MGUS, SMM and MM
|
Phase 2 | |
| Active, not recruiting |
NCT03855878 -
Observation of the Incidence and Natural History of MGUS in Patients Undergoing Weight Reduction Surgery
|
||
| Recruiting |
NCT05640843 -
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
|
N/A | |
| Completed |
NCT00099047 -
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
|
Phase 2 | |
| Completed |
NCT00919139 -
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
|
N/A | |
| Not yet recruiting |
NCT05114109 -
Isatuximab in Type I Cryoglobulinemia
|
Phase 2 | |
| Recruiting |
NCT04114084 -
Sleep Apnea in Patients With MGUS and MM
|
||
| Recruiting |
NCT06383143 -
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
|
||
| Withdrawn |
NCT01571726 -
Imaging Studies and the Development of Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT01408225 -
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
|
||
| Recruiting |
NCT05136807 -
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
|
||
| Active, not recruiting |
NCT04920084 -
A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
|
N/A | |
| Recruiting |
NCT06046287 -
Daratumumab for Polyneuropathy Associated With MGUS
|
Phase 2 |